Structure Therapeutics Inc
GPCRHealthcare|Biotechnology|USA
$53.38
-1.79 (-3.25%)
Tangible Book
$20.36
About
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
Stock Price
+182.4%(1Y)
Pipeline Summary
10 total trials3
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
Unknown: 1Active: 3NOT_YET_RECRUITING: 2Completed: 3Recruiting: 1
Active Trials (4)
Aleniglipron Phase 2 in Type 2 Diabetes Mellitus
NCT07400588Obese
Phase 2Active
Enrollment: 58 participants
Aleniglipron Phase 2 Body Composition Study
NCT07169942Obesity, Overweight, or Chronic Weight Management
Phase 2Active
Enrollment: 71 participants
A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
NCT06693843Obesity, Overweight, or Chronic Weight Management
Phase 2Active
Enrollment: 220 participants
Covid-19 Effects on Arterial Stiffness and Vascular Aging (CARTESIAN)
NCT04558450Covid19
N/ARecruiting
Enrollment: 360 participants
BioScore
5.1/10
Watchlist
Ownership
Recent News
2026-06-17 21:00:07
Data last updated: Jul 13, 2026, 12:41 PM